(NASDAQ: IMNN) Imunon's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.17%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.43%.
Imunon's earnings in 2025 is -$14,329,403.On average, 6 Wall Street analysts forecast IMNN's earnings for 2025 to be -$16,363,452, with the lowest IMNN earnings forecast at -$23,048,533, and the highest IMNN earnings forecast at -$8,994,602. On average, 5 Wall Street analysts forecast IMNN's earnings for 2026 to be -$11,659,055, with the lowest IMNN earnings forecast at -$14,128,848, and the highest IMNN earnings forecast at -$8,865,647.
In 2027, IMNN is forecast to generate -$11,315,176 in earnings, with the lowest earnings forecast at -$14,521,546 and the highest earnings forecast at -$7,737,292.